The Doctor and The Athlete: Powerhouse Duo Disrupts Functional Beverage Market with Science-Backed “Happiness” 
Angelini Pharma Announces Appointment of Sergio Marullo di Condojanni as New CEO
CEO of family company Angelini Industries will also lead the pharmaceutical company from today, bringing strong leadership experience and strategic...
Crucial Innovations Corp. Launches 4TP, a New Patient-Focused Brand of Cannabis-Based Products for Medicinal Use
4TP (“For The People”) introduces carefully cultivated CBPMs supported by transparent education and a commitment to consistent high-quality medicineLONDON, Jan....
FDA Granted Hopstem’s hNPC01 for Chronic Ischemic Stroke Approval to Enter Phase 2/3 Adaptive Pivotal Clinical Trial with Bridging Study
HOUSTON, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Hopstem Biotechnology Inc. (hereinafter referred to as "Hopstem"), a company dedicated to the...
Anteris Technologies Global Corp. Announces Pricing of $200 Million Public Offering
MINNEAPOLIS and BRISBANE, Australia, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR),...
Vivos Therapeutics Announces Closing of Exercise of Warrants for $4.64 Million Gross Proceeds
LITTLETON, Colo., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (Nasdaq: VVOS), a leading medical...
Tempest Announces Record Date for Anticipated Dividend Distribution of Warrants to Stockholders
BRISBANE, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company with a...
Clearmind Medicine Inc. Files Annual Report on Form 20-F for the Fiscal Year Ended October 31, 2025
Vancouver, Canada, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a...
Anteris Technologies Global Corp. Announces Proposed $200 Million Public Offering of Common Stock and Strategic Investment from Medtronic
MINNEAPOLIS and BRISBANE, Australia, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR),...
BioAge Announces Proposed Public Offering
EMERYVILLE, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (Nasdaq: BIOA) (“BioAge”, “the Company”), a clinical-stage biopharmaceutical company...
Erasca Announces Proposed Public Offering of $150 Million of Common Stock
SAN DIEGO, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on...
Corvus Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
SOUTH SAN FRANCISCO, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today...
Edison Issues Report on Noctiluca (NCL)
London, United Kingdom--(Newsfile Corp. - January 21, 2026) - Edison issues report on Noctiluca (WSE: NCL).Noctiluca is a dynamic advanced...
CBIH Evaluates a Potential Reg A Offering of Approximately $1,000,000 to Enable Commercial Launch, Statewide Educational Expansion, and Protection of Its Patent Portfolio
Houston, Texas--(Newsfile Corp. - January 21, 2026) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company trading on...
Women in Life Science Denmark (WiLD) expands Nordic footprint with launch of WiLD Finland
WiLD strengthens Nordic collaboration across Denmark, Finland, Norway and SwedenCOPENHAGEN, Denmark and HELSINKI, Jan. 21, 2026 /PRNewswire/ -- Women in...
LeapSpace goes live: the Research-Grade AI-Assisted Workspace built on trusted science
Leading publishers and societies join LeapSpace at launch, with 18+ million full-text research articles and books already includedLONDON, Jan. 21, 2026...
Sigrid Enters Exclusive Global Licensing and Research Collaboration to Commercialize SiPore® in Consumer Oral Health
STOCKHOLM, Jan. 21, 2026 /PRNewswire/ -- Sigrid Therapeutics (Sigrid) is a Swedish, science-driven consumer health company with a primary focus on...
BioNxt Reports Final Preclinical Results Demonstrating Approximately 40% Higher Cladribine Delivery for the Treatment Multiple Sclerosis (MS)
VANCOUVER, BC / ACCESS Newswire / January 21, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased...
Defence Therapeutics Sharpens Strategic Focus on Precision Drug Delivery to Unlock the Full Potential of Cancer Biologics
Montreal, Quebec--(Newsfile Corp. - January 21, 2026) - Defence Therapeutics Inc., (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the...
Defence Therapeutics Sharpens Strategic Focus on Precision Drug Delivery to Unlock the Full Potential of Cancer Biologics
Montreal, Quebec--(Newsfile Corp. - January 21, 2026) - Defence Therapeutics Inc., (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the...
SoftWriters Strengthens Leadership Team with Addition of LiAna Tschen and Strategic Role Expansions
New VP of Platform Operations hire and executive promotions accelerate innovation, operational excellence, and customer success for LTC pharmacy partners....